WASHINGTON — The Senate is taking pains to avoid another Aduhelm controversy.
In new bipartisan legislation unveiled on Friday, senators included language that would create a “coordinating council” meant to ensure officials across the entire Food and Drug Administration stay in sync when considering medicines under the controversial accelerated approval pathway.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
